374 related articles for article (PubMed ID: 26883192)
1. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
Xu X; Liu Z; Wang J; Xie H; Li J; Cao J; Zhou L; Zheng S
Oncotarget; 2016 Mar; 7(12):13730-41. PubMed ID: 26883192
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values.
Luk JM; Lam CT; Siu AF; Lam BY; Ng IO; Hu MY; Che CM; Fan ST
Proteomics; 2006 Feb; 6(3):1049-57. PubMed ID: 16400691
[TBL] [Abstract][Full Text] [Related]
3. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
[TBL] [Abstract][Full Text] [Related]
4. Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients.
Tan GS; Lim KH; Tan HT; Khoo ML; Tan SH; Toh HC; Ching Ming Chung M
J Proteome Res; 2014 Nov; 13(11):4833-46. PubMed ID: 24946162
[TBL] [Abstract][Full Text] [Related]
5. Differential Proteomic Analysis of Hepatocellular Carcinomas from
Lambrecht C; Ferreira GB; Omella JD; Libbrecht L; DE Vos R; Derua R; Mathieu C; Overbergh L; Waelkens E; Janssens V
Cancer Genomics Proteomics; 2020; 17(6):669-685. PubMed ID: 33099469
[TBL] [Abstract][Full Text] [Related]
6. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
[TBL] [Abstract][Full Text] [Related]
7. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
[TBL] [Abstract][Full Text] [Related]
8. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma.
Cheng J; Xie HY; Xu X; Wu J; Wei X; Su R; Zhang W; Lv Z; Zheng S; Zhou L
Cancer Lett; 2011 Nov; 310(1):35-45. PubMed ID: 21763068
[TBL] [Abstract][Full Text] [Related]
9. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma.
Lee NP; Leung KW; Cheung N; Lam BY; Xu MZ; Sham PC; Lau GK; Poon RT; Fan ST; Luk JM
Proteomics; 2008 May; 8(10):2136-49. PubMed ID: 18425728
[TBL] [Abstract][Full Text] [Related]
10. Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Zhang D; Lim SG; Koay ES
Int J Oncol; 2007 Sep; 31(3):577-84. PubMed ID: 17671684
[TBL] [Abstract][Full Text] [Related]
11. Proteome Differences between Hepatitis B Virus Genotype-B- and Genotype-C-Induced Hepatocellular Carcinoma Revealed by iTRAQ-Based Quantitative Proteomics.
Wei D; Zeng Y; Xing X; Liu H; Lin M; Han X; Liu X; Liu J
J Proteome Res; 2016 Feb; 15(2):487-98. PubMed ID: 26709725
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues.
Li N; Long Y; Fan X; Liu H; Li C; Chen L; Wang Z
J Exp Clin Cancer Res; 2009 Aug; 28(1):122. PubMed ID: 19715608
[TBL] [Abstract][Full Text] [Related]
13. Differential proteomic analysis of hepatocellular carcinoma.
Corona G; De Lorenzo E; Elia C; Simula MP; Avellini C; Baccarani U; Lupo F; Tiribelli C; Colombatti A; Toffoli G
Int J Oncol; 2010 Jan; 36(1):93-9. PubMed ID: 19956837
[TBL] [Abstract][Full Text] [Related]
14. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.
Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Yu CY; Lu FJ; Chow LP
J Proteome Res; 2005; 4(6):2062-9. PubMed ID: 16335951
[TBL] [Abstract][Full Text] [Related]
15. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.
Yi X; Luk JM; Lee NP; Peng J; Leng X; Guan XY; Lau GK; Beretta L; Fan ST
Mol Cell Proteomics; 2008 Feb; 7(2):315-25. PubMed ID: 17934217
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma.
Park KS; Kim H; Kim NG; Cho SY; Choi KH; Seong JK; Paik YK
Hepatology; 2002 Jun; 35(6):1459-66. PubMed ID: 12029631
[TBL] [Abstract][Full Text] [Related]
17. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
[TBL] [Abstract][Full Text] [Related]
18. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
19. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach.
Qiao B; Wang J; Xie J; Niu Y; Ye S; Wan Q; Ye Q
Int J Mol Med; 2012 May; 29(5):832-40. PubMed ID: 22344546
[TBL] [Abstract][Full Text] [Related]
20. Proteome analysis of hepatocellular carcinoma.
Lim SO; Park SJ; Kim W; Park SG; Kim HJ; Kim YI; Sohn TS; Noh JH; Jung G
Biochem Biophys Res Commun; 2002 Mar; 291(4):1031-7. PubMed ID: 11866469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
